Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript

Daniel Bohsen : Thank you, Doug. Thank you, Michael. And this concludes the Q&A session for this earnings call. Thank you for participating and please feel free to contact Investor Relations as always regarding any follow-up questions you might have. Before we close the call, I would like to hand over to you Lars for the final remarks.

Lars Fruergaard Jørgensen : Thank you, Daniel, and thank you all for joining us today. So I hope it comes across that we’re very pleased with the momentum of our business right now as evidenced by the sales performance in the first three months and at least the development in script for both Ozempic and Wegovy in the U.S., really proving that we are on track of scaling supplies here during the year. But also our commitment to scale supplies significantly for the coming years to treat even more patients. We’re also excited about our pipeline progress and what we have coming up in terms of Mim8 and CagriSema. And on a final note, I’d like to thank you Daniel. This was the last quarter with you at Helmuth as IR Head. Thank you for your leadership and best of luck with your continued career onwards. With this we close the call. Thank you all.

Operator: Thank you. This concludes today’s conference call. Thanks for participating. You may now disconnect.